Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial.
Melissa HardyPatrick N A HarrisDavid L PatersonMark D ChatfieldYin Monull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
The application of the win ratio methodology to the MERINO trial data illustrates its utility and feasibility for use in antimicrobial trials.